Making a difference to the people we help treat by creating value and improving healthcare outcomes through connecting innovative manufacturers with Australasian customers.

NEW AccuPlex™ SARS-CoV-2, Flu A+B and RSV reference material

Products are for professional/laboratory use only.  

AccuPlex™ SARS-CoV-2 & Flu Multiplexed Quality Solutions

AccuPlex™ SARS-CoV-2, Flu A+B and RSV Verification Panel and Reference Material Kit offer a complete Quality Solution designed for use with multiplexed molecular assays that can detect SARS-CoV-2, influenza A+B and respiratory syncytial virus (RSV). These reference materials are designed to challenge the entire molecular test procedure ensuring clinical laboratories can have confidence in their multiplex assay results.

 AccuPlexSARS-CoV-2, Flu A/B and RSV Reference Material Kit is designed to measure day-to-day performance of the assay, providing both a positive and a negative reference solution.

AccuPlexSARS-CoV-2, Flu A+B and RSV Verification Panel is optimized for assay verification at installation by documenting test performance along the assay’s range, enabling laboratories to establish lower limits of detection, perform assay comparisons, and evaluate staff proficiency.


 

 

 

 

 

Not for in vitro diagnostic use. Research Use Only.

 

 

 

 

 

 

f


Please contact us to request an insert sheet

Contact Us >



Request a Quote

Request Quote

Recent Posts

Fungal Infection – Assays and Controls*

IMMY | Vircell IMMY’s rapid fungal assays and Vircell’s external controls deliver reliable, room temperature diagnostics with built-in quality assurance for streamlined serology workflows. Vircell…

Read full article

Vircell – VirClia Extraction Tube

Discover Vircell’s VirClia Extraction Tube, an innovative pre-dispensed tube featuring a one-step filtering process that eliminates the need for centrifugation, thereby significantly simplifying the pre-analytical…

Read full article

Advancing Sepsis Diagnostics—Journal of Clinical Medicine (JCM), Honors SeptiCyte RAPID* Study

  Immunexpress are delighted to announce that the study, “Validation of SeptiCyte® RAPID to Discriminate Sepsis from Non-Infectious Systemic Inflammation,” has been selected as an Editor’s Choice Paper for 2024 by the Journal of Clinical Medicine (JCM) MDPI Editorial Team. This honour…

Read full article